Statement of policy intent: Relaunch of the Innovative Licensing and Access Pathway

Summary

On 6th November, UK Government published this statement, prepared jointly by MHRA, NICE, SMC, AWTTC and NHS partners.

The Innovative Licensing and Access Pathway (ILAP) is entering a new era with a refreshed offer to applicants. The ILAP is focussed on getting the most transformative new medicines to patients in the National Health Service (NHS) more quickly.

The ILAP is a unique initiative which aims to accelerate the time to patient care for transformative medicines and medicine-device combinations, facilitating patient access by providing a single integrated platform for sustained collaborative working between the developer, the Regulator (MHRA), the UK Health Technology Assessment (HTA) bodies and the National Health Service (NHS).

The new ILAP will continue to target timely patient benefit, take forward lessons learnt from ILAP to date and respond to the needs of our fast-paced life sciences sector by providing a more compelling offer of support to the medicine developer. This will include more focused entry criteria and an extension of the partnership to directly involve the NHS.

Read the full statement below: